AYTU BIOPHARMA, INC Cash and Cash Equivalents, Period Increase (Decrease)
AYTU BIOPHARMA, INC (AYTU) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$10.17 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-11-12
- AYTU BIOPHARMA, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2020-09-30 was -$10.17M.
- AYTU BIOPHARMA, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2020-06-30 was -$14.18M.
- AYTU BIOPHARMA, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2020-03-31 was $57.01M.
- AYTU BIOPHARMA, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2019-12-31 was -$1.75M, a 112.67% decline year-over-year.
- AYTU BIOPHARMA, INC cash and cash equivalents, period increase (decrease) for fiscal 2020 was $37.04M, a 785.74% increase from fiscal 2019.
- AYTU BIOPHARMA, INC cash and cash equivalents, period increase (decrease) for fiscal 2019 was $4.18M, a 32.93% decline from fiscal 2018.
- AYTU BIOPHARMA, INC cash and cash equivalents, period increase (decrease) for fiscal 2018 was $6.23M.
- AYTU BIOPHARMA, INC cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$7.18M, a 1123.58% decline from fiscal 2016.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2020-09-30 | -$10.17M 10-Q · filed 2020-11-12 | -$24.35M derived: sum of 2 quarters · filed 2020-11-12 | $32.65M derived: sum of 3 quarters · filed 2020-11-12 | $30.90M derived: sum of 4 quarters · filed 2020-11-12 |
| 2020-06-30 | -$14.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $42.82M derived: sum of 2 quarters · filed 2020-10-06 | $41.07M derived: sum of 3 quarters · filed 2020-10-06 | $37.04M 10-K · filed 2020-10-06 |
| 2020-03-31 | $57.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-15 | $55.25M derived: sum of 2 quarters · filed 2020-05-15 | $51.22M 10-Q · filed 2020-05-15 | $47.77M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-12-31 | -$1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-14 | -$5.78M 10-Q · filed 2020-02-14 | -$9.24M derived: sum of 3 quarters · filed 2020-11-12 | -$12.39M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-09-30 | -$4.03M 10-Q · filed 2020-11-12 | -$7.48M derived: sum of 2 quarters · filed 2020-11-12 | -$10.64M derived: sum of 3 quarters · filed 2020-11-12 | $3.20M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | -$6.61M derived: sum of 2 quarters · filed 2020-10-06 | $7.23M derived: sum of 3 quarters · filed 2020-10-06 | $4.18M 10-K · filed 2020-10-06 |
| 2019-03-31 | -$3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-15 | $10.68M derived: sum of 2 quarters · filed 2020-05-15 | $7.64M 10-Q · filed 2020-05-15 | $2.67M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $13.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-14 | $10.79M 10-Q · filed 2020-02-14 | $5.82M derived: sum of 3 quarters · filed 2020-02-14 | $13.92M derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-09-30 | -$3.05M 10-Q · filed 2019-11-14 | -$8.02M derived: sum of 2 quarters · filed 2019-11-14 | $81.15K derived: sum of 3 quarters · filed 2019-11-14 | -$3.03M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | -$4.97M derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $3.13M derived: sum of 2 quarters · filed 2019-09-26 | $15.63K derived: sum of 3 quarters · filed 2019-09-26 | $6.23M 10-K · filed 2019-09-26 |
| 2018-03-31 | $8.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-14 | $4.98M derived: sum of 2 quarters · filed 2019-05-14 | $11.20M 10-Q · filed 2019-05-14 | $8.54M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | -$3.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-14 | $3.11M 10-Q · filed 2019-05-14 | $438.45K derived: sum of 3 quarters · filed 2019-05-14 | -$1.32M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-09-30 | $6.22M 10-Q · filed 2018-11-07 | $3.55M derived: sum of 2 quarters · filed 2018-11-07 | $1.79M derived: sum of 3 quarters · filed 2018-11-07 | $4.27M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | -$2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | -$4.43M derived: sum of 2 quarters · filed 2018-09-06 | -$1.95M derived: sum of 3 quarters · filed 2018-09-06 | -$7.18M 10-K · filed 2018-09-06 |
| 2017-03-31 | -$1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-14 | $721.02K derived: sum of 2 quarters · filed 2018-05-14 | -$4.51M 10-Q · filed 2018-05-14 | -$5.12M derived: sum of 4 quarters · filed 2018-05-14 |
| 2016-12-31 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-08 | -$2.75M 10-Q · filed 2018-02-08 | -$3.36M derived: sum of 3 quarters · filed 2018-02-08 | -$5.65M derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-09-30 | -$5.23M 10-Q · filed 2017-11-09 | -$5.84M derived: sum of 2 quarters · filed 2017-11-09 | -$8.14M derived: sum of 3 quarters · filed 2017-11-09 | -$7.24M derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | -$611.64K derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | -$2.91M derived: sum of 2 quarters · filed 2017-08-31 | -$2.01M derived: sum of 3 quarters · filed 2017-08-31 | $701.13K 10-K · filed 2017-08-31 |
| 2016-03-31 | -$2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-11 | -$1.40M derived: sum of 2 quarters · filed 2017-05-11 | $1.31M 10-Q · filed 2017-05-11 | $7.17M derived: sum of 4 quarters · filed 2017-05-11 |
| 2015-12-31 | $890.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $3.61M 10-Q · filed 2017-02-09 | $9.47M derived: sum of 3 quarters · filed 2017-02-09 | $10.80M derived: sum of 4 quarters · filed 2017-02-09 |
| 2015-09-30 | $2.72M 10-Q · filed 2016-11-07 | $8.58M derived: sum of 2 quarters · filed 2016-11-07 | $9.91M derived: sum of 3 quarters · filed 2016-11-07 | $9.02M derived: sum of 4 quarters · filed 2016-11-07 |
| 2015-06-30 | $5.86M derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-01 | $7.19M derived: sum of 2 quarters · filed 2016-09-01 | $6.30M derived: sum of 3 quarters · filed 2016-09-01 | $4.71M 10-K · filed 2016-09-01 |
| 2015-03-31 | $1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-11 | $439.63K derived: sum of 2 quarters · filed 2016-05-11 | -$1.15M 10-Q · filed 2016-05-11 | -$2.63M derived: sum of 4 quarters · filed 2016-05-11 |
| 2014-12-31 | -$890.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-11 | -$2.48M 10-Q · filed 2016-02-11 | -$3.96M derived: sum of 3 quarters · filed 2016-02-11 | |
| 2014-09-30 | -$1.59M 10-Q · filed 2015-11-06 | -$3.07M derived: sum of 2 quarters · filed 2015-11-06 | ||
| 2014-06-30 | -$1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-28 | -$274.05K 10-K · filed 2015-09-28 | ||
| 2014-03-31 | $1.21M 10-Q · filed 2015-05-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |